Amgen 4Q Revenues: $3.8 billion (+17%) 4Q Earnings: $833 million (+1%) FY Revenues: $14.3 billion (+15%) FY Earnings: $3 billion (-20%) Comments: Revenue growth was driven by Aranesp, with sales up 27% to $1.1 billion in the quarter. For the year, Aranesp sales were $4.1 billion, up 26%. Epogen sales increased 6% to $661 million in the quarter and sales for the year were $2.5 billion, up 2%. Combined worldwide sales of Neulasta and Neupogen, were up 10% to $1 billion in the qu...